Advertisement

Picture EBD Group BIO-Europe Spring 2025 Milan to 28 Feb 650x100px
Organisation › Details

OncoC4 Inc.

Based in Rockville, Maryland, OncoC4 is a privately held, late clinical-stage biopharmaceutical company that is actively engaged in the discovery and development of novel biologicals for cancer treatment. Its lead clinical candidate is ONC-392, a next generation anti-CTLA-4 antibody that allows CTLA-4 to recycle and maintain its protective function against autoimmune diseases while enhancing anti-tumor activity at the same time. In addition, OncoC4 has a pipeline of first-in-class preclinical product candidates focusing on the CD24-Siglecs cancer immune evasion pathway. *

 

Period Start 2020-11-23 splitoff (date ca.)
Products Industry antibody cancer drug
  Industry 2 drug development
     
Region Region Rockville, MD
  Country United States (USA)
  Street 9640 Medical Center Drive
  City 20850 Rockville, MD
    Address record changed: 2023-03-23
     
Basic data Employees n. a.
     
    * Document for »About Section«: BioNTech AG. (3/20/23). "Press Release: BioNTech and OncoC4 Announce Strategic Collaboration to Co-Develop and Commercialize Novel Checkpoint Antibody in Multiple Solid Tumor Indications". Mainz & Rockville, MD.
     
   
Record changed: 2023-11-10

Advertisement

Picture EBD Group ChinaBio Partnering Forum 2025 Shanghai 650x200px

More documents for OncoC4 Inc.


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture EBD Group BIO-Europe Spring 2025 Milan to 28 Feb 650x300px




» top